Long Live You
Welcome to Cambridge Nutraceuticals. Our goal is to help people live longer, healthier lives.
We create supplements as they should be – easy to absorb, with proven clinical benefits. Our first product, ATERONON HEART+, was developed through £12 million in research funding and was clinically tested at Cambridge University Hospital NHS Foundation Trust to prove its effectiveness.
In 2015, we used this rigorous scientific approach and our partnerships with some of the world’s leading research institutions to create our FutureYou range of health supplements. Every FutureYou product is the focus of multiple clinical trials and is manufactured using the highest quality ingredients. TURMERIC+, the most popular of our Joint Health supplements and the focus of significant press coverage, is now supported by 30 published studies.
Based in Cambridge, the world-famous research hub, Cambridge Nutraceuticals was founded in 2012 and has grown rapidly, winning the confidence of customers, investors and internationally renowned research groups. We sell direct-to-customer within the UK and reach international purchasers through our overseas distributors, with Australia being an especially important market.
We stay at the cutting edge of research, with an ongoing programme for clinical evaluation of our innovative products, and we put people first: thanks to the health benefits of our supplements and the dedication to customer service shown by the FutureYou team, our customers have awarded us five stars for excellence on the independent review platform TrustPilot.
Research and development supported by a high-profile medical board
Our medical advisory board includes some of the world’s leading scientists and doctors, including Professor Alf Lindberg, a former member of the Nobel Committee and Secretary of the Prize in Physiology or Medicine; Peter Kirkpatrick BSc MBCHB MSc FRCS, a leading Cambridge University vascular neurosurgeon; Dr Nicholas Shenker, a consultant rheumatologist and expert in chronic pain syndromes; and Professor Michael Heinrich, Head of University College London's Centre for Pharmacognosy and Phytotherapy.